Cagrilintide with Semaglutide

The receipt

Evidence on the combination

Controlled trials

Garvey et al., 2025 · Davies et al., 2025 · Frias et al., 2023

What each does alone

• Weight loss · Weekly shotCagrilintideAmylinThe other half of Novo's CagriSema combo. Alone it's gray-market; paired, 20.4% weight loss at 68 weeks.Controlled trialsGray marketChecked Oct 24
• Weight loss · Weekly shotSemaglutideGLP-1The weekly shot the FDA approved as Ozempic and Wegovy. Weight loss in its main trial: 14.9%, on average.Approved drugFDA approvedChecked Oct 18

Mechanism overlap · reasoning, not evidence

Cagrilintide

Peptide — Long-Acting Amylin Analog

Semaglutide

GLP-1 Receptor Agonist — Metabolic

Reasoning, not evidence: what each is described to do says nothing about what they do together.

What the studies found

REDEFINE 1, Phase 3, obesity without diabetes (Garvey et al., 2025)

• What was given — 3,417 adults with obesity, or overweight with a complication, randomized 21:3:3:7 to the combination (2.4 mg each, weekly), semaglutide alone, cagrilintide alone or placebo, for 68 weeks.
• What it found — Weight changed −20.4% with the combination and −3.0% with placebo. Gastrointestinal adverse events affected 79.6% and 39.9%, mainly transient and mild to moderate.
• Limits — Funded by Novo Nordisk.

REDEFINE 2, Phase 3, obesity with type 2 diabetes (Davies et al., 2025)

• What was given — 1,206 adults with type 2 diabetes and a BMI of 27 or more, randomized 3:1 to the combination (2.4 mg each, weekly) or placebo for 68 weeks.
• What it found — Weight changed −13.7% vs −3.4%. HbA1c reached 6.5% or less in 73.5% vs 15.9%. Gastrointestinal adverse events: 72.5% vs 34.4%.
• Limits — Funded by Novo Nordisk.

Phase 2, type 2 diabetes (Frias et al., 2023)

• What was given — 92 adults with type 2 diabetes, 32 weeks, randomized to the combination, semaglutide or cagrilintide (each escalated to 2.4 mg weekly).
• What it found — HbA1c fell 2.2, 1.8 and 0.9 points: better than cagrilintide, not significantly better than semaglutide. Weight fell 15.6%, 5.1% and 8.1%.
• Limits — Small and 32 weeks long; funded by Novo Nordisk.

As a product the pair is Novo Nordisk's CagriSema; the CagriSema page has its FDA review status.